Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 10, 2017Cardiovascular DiabetologyOpen Access

DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does acute treatment with linagliptin alter BNP and NT-proBNP levels in patients with type 2 diabetes?

Population

46 patients with type 2 diabetes (T2D) with and without chronic kidney disease (CKD) (18 with CKD)

Comparison

Linagliptin for 4 days vs Placebo for 4 days

Design

RCT, randomized cross-over, placebo-controlled

Follow-up

4 days

Authors

GFGian Paolo FadiniCross-Cutting CardiologyBBBenedetta Maria BonoraUniversity of PaduaMAMattia AlbieroUniversity of Padua

Discussion

Loading...

Member takes

Implication

Linagliptin does not alter BNP or NT-proBNP levels in type 2 diabetes; confirms no assay interference and supports reliable biomarker use in this population.

Structured PICO

Does acute treatment with linagliptin alter BNP and NT-proBNP levels in patients with type 2 diabetes?

P
Population
46 patients with type 2 diabetes (T2D) with and without chronic kidney disease (CKD) (18 with CKD)
I
Intervention
Linagliptin for 4 days
C
Comparator
Placebo for 4 days
O
Outcome
Changes from baseline in BNP and NT-proBNP levels at the end of a 4-day treatmentsurrogate

Acute treatment with the DPP-4 inhibitor linagliptin does not significantly alter BNP or NT-proBNP levels measured by standard immunoassays in patients with type 2 diabetes.

Limitations

  • routinely used immunoassays do not discriminate between intact/active and cleaved BNP

Cite This Study

Fadini et al. (2017) studied this question.

synapsesocial.com/papers/6a1d36fc43708a372d5de89fhttps://doi.org/10.1186/s12933-017-0507-9
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure.1991 · 417 citations
  2. 2Renal Insufficiency and Heart Failure2004 · 705 citations
  3. 3Associations of Dipeptidyl Peptidase-4 Inhibitors with Mortality in Hospitalized Heart Failure Patients with Diabetes Mellitus2015 · 33 citations
  4. 4Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database2015 · 110 citations
  5. 5Impact of Either GLP-1 Agonists or DPP-4 Inhibitors on Pathophysiology of Heart Failure2015 · 14 citations